Stock News

The Risks and Rewards of Investing in Natural Gas ETFs The Dangers of Long-Term Investment in ProShares Ultra Bloomberg Natural Gas ETF Investing in the ProShares Ultra Bloomberg Natural Gas ETF may seem like a smart move for those looking to capitalize on the natural gas market. However, long-term investors should be cautious due to…

AppFolio: A High-Quality Investment with Impressive Growth Trajectory Beating Expectations and Setting New Benchmarks AppFolio, a leading provider of comprehensive platform solutions, has recently delivered stellar Q3 results that have left Wall Street impressed. Not only did the company surpass analysts’ expectations by a wide margin, but it also raised its full-year outlook, signaling a…

Biogen Announces Promising Results for IgA Nephropathy Treatment A Breakthrough in Kidney Disease Research Imagine a world where kidney disease is no longer a life-threatening condition. Well, thanks to Biogen Inc.’s latest study, that dream may soon become a reality. The Phase 2 IGNAZ study has shown incredible promise in treating IgA nephropathy (IgAN) with…

Welcome to the Weird and Wonderful World of Immunological Diseases Brisbane, Calif. – October 26, 2024 Step right up, ladies and gents, and let me introduce you to Vera Therapeutics, Inc. This company, with its fancy Nasdaq listing (VERA), is doing some truly magical things in the world of biotechnology. Specifically, they are on a…

Celldex Therapeutics Announces Positive Results from Phase 2 Clinical Trial Overview Hampton, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) revealed encouraging outcomes today from their Phase 2 clinical trial of barzolvolimab in chronic inducible urticaria (CIndU). The trial focused on two common forms of CIndU: cold urticaria (ColdU) and symptomatic dermographism…

Mallinckrodt plc Announces Poster Presentation on TERLIVAZ® at Kidney Week 2024 Introduction Mallinckrodt plc, a global specialty pharmaceutical company, presented a pooled analysis from Phase 3 clinical trials highlighting liver transplant rates in adult patients with Hepatorenal Syndrome (HRS) with rapid reduction in kidney function treated with TERLIVAZ. The presentation took place at Kidney Week…

Welcome to Swedbank’s Third Quarter Earnings Conference Call October 23, 2024 3:45 AM ET Good morning and thank you for dialing into Swedbank’s Third Quarter 2024 Results Presentation. My name is Annie Ho from Investor Relations, and we also have our C-suite here today, including Jens Henriksson – President and Chief Executive Officer, Anders Karlsson…

Annuities vs. ETFs: A Detailed Comparison Introduction When it comes to investing, there are a plethora of options available in the market. Annuities have long been considered a popular choice for individuals seeking guaranteed protection and income in retirement. On the other hand, Exchange-Traded Funds (ETFs) have gained traction due to their liquidity and lower…